Navigation Links
Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Date:11/5/2013

PHILADELPHIA, Nov. 5, 2013 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NASDAQ: ARIA) stock between December 11, 2011 and October 31, 2013, inclusive. The investigation concerns whether Ariad and certain of its officers and/or directors disseminated materially false and misleading information to investors in violation of Sections 10(b), and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, promulgated thereunder.

Ariad describes itself as an oncology company, focused on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer, and other difficult-to-treat cancers.  On October 9, 2013, Ariad disclosed that Iclusig, a drug the FDA approved in December, 2012 as a last-line treatment for certain kinds of chronic myeloid leukemia, had shown higher than expected rates of serious health problems related to blood clots. Two days later, the U.S. Food and Drug Administration announced it was investigating severe and life-threatening blood clots and narrowing of blood vessels in current patients taking the medication. On October 18, 2013 the Company announced it had agreed to terminate a trial of the drug in newly-diagnosed patients because arterial thrombotic events were observed in patients taking Iclusig. On October 31, 2013, at the FDA's request, the Company disclosed that it was suspending sales of the drug.

Upon its October 31, 2013, disclosure that it was suspending sales of Iclusig, Ariad shares declined $2.07 per share or over 30%, to close at $4.70 per share. As of November 4, 2013, Ariad's stock was trading at $2.98 per share, down 85 percent from its trading value before October 8, 2013.

If you wish to discuss what rights you may have related to a loss in your investment in Ariad or you have any information on Ariad's representations about the Iclusig drug, please contact Eduardo Texidor Jr. at etexidor@cprlaw.com or, toll free, at 1-888-375-7600. For those investors inquiring via email, please include "Ariad" in the subject line, and, in the body of the email, the number of shares purchased and your mailing address and telephone number.

Since 1973, Cohen, Placitella & Roth, PC has been recognized as one of the premier trial law firms in the country. The firm has extensive experience in prosecuting securities litigation involving violations of the federal securities laws, state law derivative actions and mergers and acquisitions cases, representing institutional investors such as public pension plans and union pension funds as well as individual shareholders suffering substantial investment losses due to corporate misconduct. LexisNexis Martindale-Hubbell® annually reports Cohen, Placitella & Roth's peer rating-the highest AV® - "a testament to professional excellence." Since the inauguration of its "Best Law Firms"' edition in 2010, U.S. News and World Report has annually listed Cohen, Placitella & Roth as one of the top-tier class action law firms in the country.

Contact:
Eduardo Texidor Jr.
Cohen, Placitella & Roth, PC
Toll free: 1-888-375-7600
etexidor@cprlaw.com


'/>"/>
SOURCE Cohen, Placitella & Roth, PC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
2. UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
3. Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence
4. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
7. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
8. Langland Collaboration with CISCRP to Show Participants How Their Words Can Impact a Clinical Trial
9. InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
10. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
11. French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... Pa. (PRWEB) , ... October 09, 2019 , ... “When ... the emotions, frustrations, and the realities of the HEMS world through telling the real ... Helicopter Pilot” is the creation of published author Jay A. Humphrey, an EMS helicopter ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... Dr. Ryan ... at the 2019 Academy of Integrative Health and Medicine conference. Their presentation titled Advances ... integrative treatments and how they can be used to promote brain health, and reduce ...
(Date:10/8/2019)... ... 08, 2019 , ... Dr. Eric Baker and Dr. Tim ... dental and medical training to offer medically compromised patients predictable and ... diabetes, and other systemic concerns for dental implants and other oral surgeries to ...
Breaking Medicine Technology:
(Date:10/17/2019)... Calif. (PRWEB) , ... October 17, 2019 , ... Knotty ... magnetic roller case, quickly broke its campaign goal– raising more than $20,000 in only ... response from the crowdfunding community, who’ll be the first to enjoy the ease of ...
(Date:10/15/2019)... , ... October 14, 2019 , ... Khalieghya Dandie-Evans, a ... to ride atop the Donate Life Rose Parade® float in the 131st Rose Parade® ... and tissue donation across Northern California and Northern Nevada, the organization’s service area. , ...
(Date:10/15/2019)... , ... October 15, 2019 , ... Genomenon® ... with SOPHiA GENETICS that includes incorporating the Mastermind® Genomic Search Engine ... the most up-to-date genomic research at the fingertips of clinical researchers performing genomic analysis ...
(Date:10/11/2019)... ... ... A Topping Out event was hosted today at the construction site of the Southwest ... event celebrated reaching the final height of the structure set to open in the ... in Texas, STA’s facility will be home to an organ recovery center including a ...
(Date:10/10/2019)... ... 10, 2019 , ... In attendance at this year’s ISSN ... the significant results of an independent study presented by researchers from the University ... poster entitled “The Acute Effects of Citrulline Malate and Bonded Arginine Silicate Supplementation ...
Breaking Medicine News(10 mins):